



The 8th International Conference of the International Mesothelioma Interest Group

**Conference Chairs:
Hedy Lee Kindler, MD and Samuel Armato, PhD**

**October 19-22, 2006
The Sheraton Chicago Hotel & Towers
Chicago, Illinois**



**Hosted by:
The University of Chicago
Pritzker School of Medicine
imig.uchicago.edu**

International Organizing Committee

Steven Albelda, Philadelphia, Pennsylvania
H. Richard Alexander, Baltimore, Maryland
Paul Baas, Amsterdam, The Netherlands
Hasan Batirel, Istanbul, Turkey
Courtney Broaddus, San Francisco, California
Raphael Bueno, Boston, Massachusetts
Sjaak Burgers, Amsterdam, The Netherlands
Helen Clayson, Cumbria, United Kingdom
Thomas Colby, Rochester, Minnesota
Jenette Creaney, Perth, Australia
Nicholas de Klerk, Subiaco, Australia
Irma Dianzani, Novara, Italy
James Entwisle, Leicester, United Kingdom
Dean Fennell, Belfast, United Kingdom
Francoise Galateau-Salle, Caen, France
Gunnar Hillerdal, Stockholm, Sweden
Raffit Hassan, Bethesda, Maryland
Aliya Husain, Chicago, Illinois
Pasi Janne, Boston, Massachusetts
Tushar K. Joshi, Delhi, India
Robert Kratzke, Minneapolis, Minnesota
Richard Lake, Perth, Australia
Christian Manegold, Mannheim, Germany
Brooke Mossman, Burlington, Vermont
Martin Muers, Leeds, United Kingdom
Steven Mutsaers, Perth, Australia
Luciano Mutti, Vercelli, Italy
Anna Nowak, Perth, Australia
Bruce Robinson, Perth, Australia
Oluf Dimitri Roe, Trondheim, Norway
Ravi Salgia, Chicago, Illinois
Rolf Stahel, Zurich, Switzerland
Jeremy Steele, London, United Kingdom
Daniel Stermann, Philadelphia, Pennsylvania
David Sugarbaker, Boston, Massachusetts
Paul Sugarbaker, Washington, DC
Joseph Testa, Philadelphia, Pennsylvania
James teWaterNaude, Capetown, South Africa
Walter Weder, Zurich, Switzerland
Chi Pang Wen, Taipei, Taiwan

PROGRAM OVERVIEW

The 8th International Conference of the International Mesothelioma Interest Group

Wednesday, October 18, 2006

7:30-9:30 pm Welcome Reception
The Signature Room
95th floor of the John Hancock Center

Thursday, October 19, 2006

7:00-8:00 Registration/Continental Breakfast

8:00-8:05 Introduction and Welcome
Hedy Lee Kindler and Samuel Armato
IMIG Conference Co-Chairs

8:05-9:55 The High-Risk Individual I
Session Chair: Joseph Testa (Philadelphia, PA) and Karl Kelsey (Boston, MA)

8:05-8:25 The mesothelioma epidemic in Cappadocia: The gene-environment interaction
Michele Carbone, Honolulu, HI

8:25-8:40 Abstract: Familial clustering of mesothelioma in subjects exposed to crocidolite at Wittenoom
Nicholas de Klerk, Subiaco, Australia

8:40-9:00 Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study
Irma Dianzani, Novara, Italy

9:00-9:20 A mouse model recapitulating genetic and signaling perturbations characteristic of human mesothelioma
Joseph Testa, Philadelphia, PA

9:20-9:40 Chemoprevention as an approach to control of carcinoma of the lung and mesothelioma
Michael Sporn, Hanover, NH

9:40-9:55 Abstract: Vitamin A and cancer prevention in workers previously exposed to asbestos in Wittenoom
Helman Alfonso, Crawley, Australia
IMIG Young Investigator Award

9:55-10:15 Break/Poster Viewing

10:15-11:40 The High-Risk Individual II

Session Chairs: Oluf Dimitri Roe (Trondheim, Norway) and Kyle Hogarth (Chicago, IL)

10:15-10:35 Biomarkers for malignant mesothelioma

Jenette Creaney, Perth, Australia

10:35-10:55 Genomics for biomarker detection in mesothelioma

Harvey Pass, New York, NY

10:55-11:10 Abstract: Diagnostic and prognostic utility of soluble mesothelin-related peptides in malignant pleural mesothelioma

Bogdan-Dragos Grigoriu, Lille, France

11:10-11:25 ALA mediated fluorescence thoracoscopy in pleural diseases

Sjaak Burgers, Amsterdam, The Netherlands

11:25-11:40 Low-dose computed tomography in prior asbestos workers

Heidi Roberts, Toronto, Canada

11:40-12:40 Lunch

12:40-2:00 Pathogenesis: How Does Asbestos Cause Cancer?

Session Chairs: Marie-Claude Jaurand (Paris, France) and Michele Carbone (Honolulu, HI)

12:40-1:00 Plasticity of the mesothelium: A stem cell in the midst?

Steven Mutsaers, Perth, Australia

1:00-1:20 Cell signaling and transcription factor activation by asbestos

Brooke Mossman, Burlington, VT

1:20-2:00 DEBATE

SV40 plays a causative role in mesothelial cell carcinogenesis

Adi Gazdar, Dallas, TX

SV40 as a significant carcinogen in human mesothelioma and other cancers: An increasingly dubious hypothesis

Marc Ladanyi, New York, NY

Moderator: Steven Albelda, Philadelphia, PA

2:00-2:30 Break/Poster Viewing

2:30-4:15 Workshop: The Clinical Relevance of Mouse Models for Mesothelioma

Co-Chairs: Richard Lake (Perth, Australia) and Sjaak Burgers (Amsterdam, The Netherlands)

2:30-2:40 Animal models: An overview

Steven Albelda, Philadelphia, PA

2:40-2:45 An SV40 TAg transgenic model of asbestos-induced mesothelioma

Richard Lake, Perth, Australia

2:45-2:55 Abstract: Gene expression profiling in an SV40 large T antigen expressing transgenic mouse mesothelioma model. Implications for a role for SV40 in human mesothelioma?

Andrew Holloway, East Melbourne, Australia

IMIG Young Investigator Award

2:55-3:00 A conditional knockout model for mesothelioma

Sjaak Burgers, Amsterdam, The Netherlands

3:00-3:10 Abstract: A conditional knockout model for malignant mesothelioma. A model for in vivo and in vitro therapeutic strategies

Johan Jongasma, Amsterdam, The Netherlands

3:10-3:20 Abstract: Loss of functional Arf predisposes mice to asbestos-induced mesothelioma

Deborah Altomare, Philadelphia, PA

3:20-3:30 Abstract: Local recurrence model of malignant pleural mesothelioma and investigation of local adjuvant treatment after surgery

Walter Weder, Zurich, Switzerland

3:30-3:40 Abstract: Development of a malignant mesothelioma model with defined genetic elements

Tan Ince, Boston, MA

3:40-3:50 Abstract: Tumor infiltrating macrophages in murine malignant mesothelioma: Targeting macrophages for tumor therapy

Bernadette Scott, Victoria, Australia

3:50-4:15 DISCUSSION

Posters

SV40 oncoproteins and p53 deficiency impair stress-induced mesothelial cell senescence

Jodie Pietruska, Providence, RI

Monitoring tumor growth by imaging of a human mesothelioma murine model

Pietro Bertino, Novara, Italy

A novel murine mesothelioma model of malignant pleural effusion

Masaki Anraku, Toronto, Canada

Clinico-pathologic features of murine mesothelioma induced by natural or synthetic fibers

Pascal Andujar, Creteil, France

2:30-4:15 Workshop: Developing the Next Generation of Clinical Trials for Mesothelioma: What are the Key Questions and How Should We Answer Them?

Co-Chairs: Anna Nowak (Perth, Australia) and Paul Baas (Amsterdam, The Netherlands)

2:30-2:45 Potential pitfalls in the evaluation of new drugs for mesothelioma: Lessons from the past
Paul Baas, Amsterdam, The Netherlands

2:45-2:55 Abstract: Prognosis of malignant pleural mesothelioma: Subtype more important than stage. A study from the Nordic Mesothelioma Groups
Gunnar Hillerdal, Stockholm, Sweden

2:55-3:10 Design issues in phase II/III clinical trials in mesothelioma
Richard Stephens, London, United Kingdom

3:10-3:25 Functional and patient-rated endpoints in clinical trials
Anna Nowak, Perth, Australia

3:25-3:40 Is there a correlation between pathologic response and radiographic response and what does this mean?
Dean Fennell, Belfast, United Kingdom

3:40-4:15 PANEL DISCUSSION
Jeremy Steele, London, United Kingdom

5:30-9:30 Field Museum Extravaganza

4:45 Trolleys depart from the Sheraton Chicago Hotel & Towers

5:30-7:30 Guided tour of the exhibition, "Tutankhamun and the Golden Age of Pharaohs"

7:30-9:30 Dinner

9:30 Trolleys return to the Sheraton Chicago Hotel & Towers

Friday, October 20, 2006

7:00-8:00 Continental Breakfast

8:00-10:05 Epidemiology I

Session Chairs: Gunnar Hillerdal (Stockholm, Sweden) and Julian Peto (London, United Kingdom)

8:00-8:20 South Africa: The first link between asbestos and mesothelioma, but not the last word?
James teWaterNaude, Capetown, South Africa

8:20-8:40 The mesothelioma epidemic: Occupational, environmental, and spontaneous cases
Julian Peto, London, United Kingdom

8:40-8:55 Abstract: The global asbestos epidemic and its reflections in the recent Japanese experience
Ro-Ting Lin, Kitakyushu, Japan
IMIG Young Investigator Award

8:55-9:10 Abstract: Risk of pleural mesothelioma: A French population-based case control study (1998-2002)
Patrick Rolland, Bordeaux, France

9:10-9:30 Health effects among World Trade Center responders
Steven Levin, New York, NY

9:30-9:50 Pleural abnormalities and exposure to asbestos-contaminated vermiculite in Libby, Montana: A twenty year follow-up study
James Lockey, Cincinnati, OH

9:50-10:05 Abstract: Mesothelioma update for Libby, Montana: Occupational and non-occupational
Bruce Case, Montreal, Canada

10:05-10:30 Break/Poster Viewing

10:30-12:20 Epidemiology II

Session Chairs: Tushar K. Joshi (Delhi, India) and Chi Pang Wen (Taipei, Taiwan)

10:30-10:50 Australia: Wittenoom and beyond
Nicholas de Klerk, Subiaco, Australia

10:50-11:05 Abstract: Age and sex differences in malignant mesothelioma after residential exposure to blue asbestos (crocidolite)
Alison Reid, Crawley, Australia

11:05-11:25 The rising toll of mesothelioma in Egypt
Rabab Gaafar, Cairo, Egypt

- 11:25-11:40 Mesothelioma in Turkey: A rural disease**
Muzaffer Metintas, Eskisehir, Turkey
- 11:40-12:00 Asbestos-related diseases from environmental exposure to crocidolite in Da-yao, China: An update study on mesothelioma and lung cancer mortality from a residentially exposed cohort and from local surveys and statistics**
Chi Pang Wen, Taipei, Taiwan
- 12:00-12:20 Asbestos use in India: Magnitude of risk and impact on health**
Tushar K. Joshi, Delhi, India
- 10:20-12:30 Workshop: Immunology and Immunotherapy of Mesothelioma**
Co-Chairs: Bruce Robinson (Perth, Australia) and Steven Albelda (Philadelphia, PA)
- 10:20-10:35 Combining immunotherapy with chemotherapy to treat mice with mesothelioma**
Richard Lake, Perth, Australia
- 10:35-10:50 What is the evidence in patients that there is any immune response to mesothelioma and/or that immunotherapy ever works?**
Bruce Robinson, Perth, Australia
- 10:50-11:00 Abstract: Targeting the tumor microenvironment: A novel immunotherapy that cures large mesothelioma tumors by engaging neutrophils, CD8+ T cells, and tumor blood vessels**
Delia Nelson, Bentley, Australia
- 11:00-11:15 Altering the tumor microenvironment to augment immunotherapy for mesothelioma**
Steven Albelda, Philadelphia, PA
- 11:15-11:45 The importance of stroma in the development and destruction of cancers**
Hans Schreiber, Chicago, IL
- 11:45-12:00 Antibody-based treatment for mesothelioma: Clinical trials and laboratory studies**
Raffit Hassan, Bethesda, MD
- 12:00-12:10 Abstract: Murine mesothelioma treatment with peri-tumoral injections of CpG alone or combined with CD40 ligand**
Richard Kornbluth, La Jolla, CA
- 12:10-12:20 Abstract: Dendritic cell-based immunotherapy for malignant pleural mesothelioma**
Joost Hegmans, Rotterdam, The Netherlands
- 12:20-12:30 Abstract: Identifying and targeting a spectrum of internalizing cell surface antigens expressed by mesothelioma**
Bin Liu, San Francisco, CA

Posters

- Immune profile of peripheral and pleural fluid T cells in malignant mesothelioma and pleural metastasis of adenocarcinoma**
Arnaud Scherpereel, Lille, France
- Stimulation of macrophage toxicity for mesothelioma cells by anti-CD14 antibody**
Marie-Marthe Phillippeaux, Geneva, Switzerland
- A photodynamic therapy generated tumor vaccine in an orthotopic murine malignant mesothelioma model**
Joseph Friedberg, Philadelphia, PA
- Chemokine receptors are rarely expressed on malignant or benign mesothelial cells**
Ben Davidson, Oslo, Norway
- Efficient induction of mesothelioma-specific cytotoxic T cell responses by cross presentation of apoptotic HSP70-overexpressing mesothelioma cells by dendritic cells**
Marc Gregoire, Nantes, France

12:20-1:45 Lunch

1:45-3:15 Genetics

- Session Chairs:** Andrew Holloway (East Melbourne, Australia) and Raphael Bueno (Boston, MA)
- 1:45-2:05 Asbestos, chromosomal deletions and tumor suppressor gene alterations in human malignant mesothelioma**
Marie-Claude Jaurand, Paris, France
- 2:05-2:20 Abstract: Asbestos-associated malignancies in the lung and pleura show distinct genetic aberrations**
Pamela Lindholm, Helsinki, Finland
- 2:20-2:40 Proteomic methods to identify novel therapeutic targets in malignant mesothelioma**
Pasi Janne, Boston, MA
- 2:40-2:55 Abstract: Gene expression profiling of malignant peritoneal mesothelioma identifies novel targets for therapeutic intervention**
Sheelu Varghese, Baltimore, MD
IMIG Young Investigator Award
- 2:55-3:15 Prognostic gene ratio test for mesothelioma validated in a prospective clinical trial**
Raphael Bueno, Boston, MA

3:15-3:40 Break/Poster Viewing

1:45-5:45 Supportive Care Satellite Symposium

Co-Chairs: Martin Muers (Leeds, United Kingdom) and Helen Clayson (Cumbria, United Kingdom)

- 1:45-2:10 The scope of supportive palliative care for malignant mesothelioma in the 21st century**
Martin Muers, Leeds, United Kingdom
- 2:10-2:35 The management of breathlessness in mesothelioma**
Sara Booth, Cambridge, United Kingdom
- 2:35-3:00 Managing pain in mesothelioma**
WWA Zurmond, Amsterdam, The Netherlands
- 3:00-3:10 *Abstract:* Malignant mesothelioma and cachexia: Description of body composition changes in 27 patients receiving chemotherapy**
Nick Pavlakis, Sydney, Australia
- 3:10-3:35 Managing effusions: When and how to intervene**
Daniel Miller, Atlanta, GA
- 3:35-3:45 *Abstract:* Pleurodesis in follow-up and treatment of malignant pleural mesothelioma patients**
Guntulu Ak, Eskisehir, Turkey
- 3:45-3:55 *Abstract:* The evaluation of local dissemination on intervention sites in malignant pleural mesothelioma patients and indications for prophylactic radiotherapy**
Huseyin Yildirim, Eskisehir, Turkey
IMIG Travel Award
- 3:55-4:10 BREAK**
- 4:10-4:35 Patients' and carers' experience of mesothelioma**
Helen Clayson, Cumbria, United Kingdom
- 4:35-4:55 The nurse's role in mesothelioma**
Tamara Guterz, Chicago, IL
- 4:55-5:20 Asbestos disease: A Canadian case study**
James Mackenzie, Sarnia, Canada
- 5:20-5:45 PANEL DISCUSSION**

Posters

Rates of thromboembolic events in patients with mesothelioma

Claire Verschraegen, Albuquerque, NM

Increased pleural fluid ADA level in patients with malignant mesothelioma: A potential predictor for the outcome of talc pleurodesis

Huseyin Yildirim, Eskisehir, Turkey

Developing a National Resource Centre for Mesothelioma in the UK

Liz Darlison, Leicester, United Kingdom

3:45-5:45 Imaging Workshop

Co-Chairs: Samuel Armato (Chicago, IL) and James Entwisle (Leicester, United Kingdom)

- 3:45-4:05 Imaging malignant pleural mesothelioma: Clinical applications and challenges**
James Entwisle, Leicester, United Kingdom
- 4:05-4:25 The evolution of imaging-based tumor response evaluation in mesothelioma**
Samuel Armato, Chicago, IL
- 4:25-4:40 *Abstract:* Use of 18F-FDG PET imaging in staging and prediction of survival for malignant pleural mesothelioma**
Anna Nowak, Perth, Australia
- 4:40-4:55 *Abstract:* Early response evaluation in malignant pleural mesothelioma by positron emission tomography with 18F-fluorodeoxyglucose**
Giovanni Luca Ceresoli, Milan, Italy
- 4:55-5:10 *Abstract:* Development of a computer model for volumetric response assessment in mesothelioma**
Binsheng Zhao, New York, NY
- 5:10-5:45 PANEL DISCUSSION**
James Entwisle (Leicester, UK), Heber MacMahon (Chicago, IL), Mylene Truong (Houston, TX) and Samuel Armato (Chicago, IL)

Posters

FDG PET/CT in malignant pleural mesothelioma: Is there a histological difference between hot and cold areas?

Peter Kestenholz, Zurich, Switzerland

Molecular bioprobes for imaging malignant mesothelioma

Ripen Misri, Vancouver, Canada

Spontaneous regression of diffuse malignant pleural mesothelioma with no treatment: Two case reports

Astero Klabatsa, London, United Kingdom

3:40-5:55 Tumor Biology: Oral Abstracts and Poster Discussion

Session Chairs: Steven Mutsaers (Perth, Australia) and Pasi Janne (Boston, MA)

- 3:40-3:55 *Abstract:* Asbestos burden, epigenetic silencing, and survival in malignant pleural mesothelioma**
Brock Christensen, Boston, MA
IMIG Young Investigator Award
- 3:55-4:10 *Abstract:* Pathway signatures of biphasic and epithelial mesothelioma identify the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors**
Charles Powell, New York, NY

- 4:10-4:25 Abstract: TNF- α inhibits asbestos-induced cytotoxicity via a NF- κ B dependent pathway: A possible mechanism for asbestos-induced oncogenesis**
Haining Yang, Honolulu, HI
- 4:25-4:40 Abstract: Oxidative stress gene modulation in pleural mesothelioma as assessed by microarray in vitro, ex-vivo, and in-situ analysis**
Bertrand Rihn, Nancy, France
- 4:40-4:55 Abstract: NF- κ B provides a survival signal to human mesothelial and mesothelioma cells exposed to asbestos fibers**
Luciano Mutti, Vercelli, Italy
- 4:55-5:05 Abstract: Semi-quantitative analysis of growth factor gene expression in the lungs and pleura by laser capture microscopy**
Arnold Brody, New Orleans, LA

Poster Discussion

Crocidolite asbestos and SV40 are co-carcinogens in human mesothelial cells and in causing mesothelioma in humans
Michele Carbone, Honolulu, HI

Microarray of normal mesothelium and mesothelioma—visceral and parietal pleura has distinct gene expression profile—consequences for oncogenesis of mesothelioma?
Oluf Dimitri Roe, Trondheim, Norway

Ras pathway activation in malignant mesothelioma
Robert Kratzke, Minneapolis, MN

5:05-5:20 Discussant: Steven Mutsaers, Perth, Australia

Alterations of the G1 checkpoints in malignant pleural mesothelioma in relation to pathogenesis and survival
Rabab Gaafar, Cairo, Egypt

An integrated analysis of chromosomal alteration and gene expression in malignant mesothelioma
Andrew Holloway, East Melbourne, Australia

Expression of Snail, Slug, and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression
Ben Davidson, Oslo, Norway

5:20-5:35 Discussant: Pasi Janne, Boston, MA

Bortezomib accelerates BAX BAK dependent mitochondrial depolarization in malignant pleural mesothelioma cells
Dean Fennell, Belfast, United Kingdom

Cisplatin-induced apoptosis in malignant pleural mesothelioma cells involves p53 but not p14ARF
Thomas Marti, Zurich, Switzerland

Anoikis resistance in malignant pleural mesothelioma cells
Julien Daubriac, Paris, France

Role of Notch signaling in human malignant mesothelioma
Irene Graziani, Maywood, IL

Bax and Bak immuno-reactivity in malignant pleural mesothelioma
Astero Klabatsa, London, United Kingdom

Inhibition of survivin and aurora B kinase radiosensitizes mesothelioma cells by enhancing mitotic arrest
Bo Lu, Nashville, TN

5:35-5:55 Discussant: Giovanni Gaudino, Novara, Italy

Posters

DNA copy number profiling in malignant pleural mesothelioma by array CGH
Pamela Lindholm, Helsinki, Finland

An integrated genomic approach to understanding the determinants of mesothelioma sensitivity to specific novel agents
Shigeki Shimizu, New York, NY

SV40 infection can promote full oncogenicity of human mesothelial cells
Maurizio Bochetta, Maywood, IL

Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients
Noriyasu Usami, Nagoya, Japan

**5:45-7:30 Reception at the Riverside Exhibition Hall Promenade
Sheraton Chicago Hotel & Towers**

Free evening to enjoy Chicago's wonderful restaurants and theaters

IMIG Board of Directors Meeting

Saturday, October 21, 2006

7:00-8:00 Continental Breakfast

8:00-10:00 Non-Pleural Mesothelioma

Session Chairs: Claire Vershraegen (Albuquerque, NM)
and H. Richard Alexander (Baltimore, MD)

- 8:00-8:15 Mesotheliomas of the pericardium and tunica vaginalis**
Raffit Hassan, Bethesda, MD
- 8:15-8:30 Understanding the terminology and pathology of peritoneal mesothelioma**
Victor Roggli, Durham, NC
- 8:30-8:45 *Abstract:* Potential of survivin as a new therapeutic target in diffuse malignant mesothelioma of the peritoneum**
Nadia Zaffaroni, Milan, Italy
- 8:45-9:05 Aggressive surgical cytoreduction with hyperthermic intraperitoneal chemoperfusion for patients with malignant mesothelioma**
James Pingpank, Bethesda, MD
- 9:05-9:20 *Abstract:* Multimodality regional therapy for peritoneal mesothelioma**
John Chabot, New York, NY
- 9:20-9:40 Diffuse malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Experience of NCI of Milan**
Marcello Deraco, Milan, Italy
- 9:40-10:00 Prospective evaluation of quality of life after tumor cytoreduction and intraperitoneal chemotherapy in patients with peritoneal mesothelioma and other peritoneal surface malignancies**
H. Richard Alexander, Baltimore, MD

Posters

- Phase II trial of vinorelbine chemotherapy in patients with malignant peritoneal mesothelioma**
Jeremy Steele, London, United Kingdom
- A systematic review on the efficacy of cytoreductive surgery combined with peri-operative chemotherapy for diffuse malignant peritoneal mesothelioma: An evolution of treatment strategies**
Paul Sugarbaker, Washington, DC
- In vitro drug resistance levels do not correlate with prognosis in patients with peritoneal mesothelioma**
Krunal Patel, New York, NY
- Critical analysis of nuclear size as an assessment of prognosis in diffuse malignant peritoneal mesothelioma**
Paul Sugarbaker, Washington, DC

8:00-10:40 Workshop: Surgical Pitfalls and Challenges for Pleural Mesothelioma: Optimizing Your Technique

David Sugarbaker (Boston, MA) and Walter Weder (Zurich, Switzerland)

- 8:00-8:20 Technical considerations of extrapleural pneumonectomy**
David Sugarbaker, Boston, MA
- 8:20-8:35 Pericardial and diaphragmatic reconstruction**
Hasan Batirel, Istanbul, Turkey
- 8:35-8:50 Techniques of intra-operative chemotherapy**
Lambros Zellos, Boston, MA
- 8:50-9:10 Operative complications: Diagnosis and treatment**
Walter Weder, Zurich, Switzerland
- 9:10-9:20 *Abstract:* Risk factors for major complications after extrapleural pneumonectomy**
Marc de Perrot, Toronto, Canada
- 9:20-9:30 *Abstract:* Management of complications following extrapleural pneumonectomy**
Hendrik Dienemann, Heidelberg, Germany
- 9:30-9:45 Pre-operative assessment and criteria for patient selection**
Loic Lang-Lazdunski, London, United Kingdom
- 9:45-9:55 *Abstract:* Invasive staging for mesothelioma reveals radiographically occult distant metastatic disease**
Joseph Friedberg, Philadelphia, PA
- 9:55-10:15 Pleurectomy/decortication for malignant pleural mesothelioma: Technique and comments**
Harvey Pass, New York, NY
- 10:15-10:40 PANEL DISCUSSION**
- 10:20-11:45 Peritoneal Mesothelioma Workshop**
Co-Chairs: Paul Sugarbaker (Washington, DC) and Raffit Hassan (Bethesda, MD)
- 10:20-10:35 Optimal treatment for patients with newly diagnosed peritoneal mesothelioma**
James Pingpank, Bethesda, MD
- 10:35-10:50 Peritoneal mesothelioma: Treatment options for patients who are not candidates for surgery**
Claire Vershraegen, Albuquerque, NM
- 10:50-11:05 Staging of peritoneal mesothelioma?**
Paul Sugarbaker, Washington, DC
- 11:05-11:25 Multi-center clinical trials for peritoneal mesothelioma: Can they be done and what are the questions to be answered?**
Raffit Hassan, Bethesda, MD

11:25-11:45 PANEL DISCUSSION

Claire Verschraegen (Albuquerque, NM), Victor Roggli (Durham, NC), James Pingpank (Bethesda, MD), Marcello Deraco (Milan, Italy) and H. Richard Alexander (Baltimore, MD)

8:00-9:55 Epidemiology III: Oral Abstracts and Poster Discussion

Session Chairs: James teWaterNaude (Capetown, South Africa) and Nicholas de Klerk (Subiaco, Australia)

8:00-8:15 Abstract: Exposure to polio vaccine possibly contaminated with simian virus 40 and subsequent risk of malignant mesothelioma
Kristina Kjaerheim, Oslo, Norway

8:15-8:30 Abstract: Malignant mesothelioma as a second primary malignancy
Sjaak Burgers, Amsterdam, The Netherlands

8:30-8:45 Abstract: The mesothelioma epidemic and the hidden asbestos lung cancer epidemic
Christine Rake, Surrey, United Kingdom

8:45-9:00 Abstract: Quantifying the risks of mesothelioma and lung cancer from environmental crocidolite exposure in Da-yao, China
Ting-Yuan David Cheng, Baltimore, MD
IMIG Young Investigator Award

9:00-9:15 Abstract: The French National Mesothelioma Surveillance Program
Marcel Goldberg, Saint-Maurice, France

Poster discussion

Quantitative estimation of the risk of lung cancer and pleural mesothelioma among automobile mechanics in France
Marcel Goldberg, Saint-Maurice, France

A cluster of 5 cases of malignant pleural mesothelioma among the faculty of a university asbestos insulated campus
Marcel Goldberg, Saint-Maurice, France

Occupational asbestos exposure, possible mesothelioma, and reimbursement
Paul Baas, Amsterdam, The Netherlands

Trend of mesothelioma morbidity in the Sverdlovsk Region of the Russian Federation
Sergey Kashansky, Ekaterinburg City, Russian Federation

9:15-9:35 Discussant: James teWaterNaude, Capetown, South Africa

9:35-9:55 Discussant: Nicholas de Klerk, Subiaco, Australia

Posters

Benign neoplasms of the pleura in the structure of mesothelioma incidence
Sergey Kashansky, Ekaterinburg City, Russian Federation

Risk assessment of malignant pleural mesothelioma related to long-term exposure to radiation factors
Sergey Kashansky, Ekaterinburg City, Russian Federation

Mesothelioma in Russia: Review of 3,259 published cases
Sergey Kashansky, Ekaterinburg City, Russian Federation

Prognostic factors and survival of malignant mesothelioma in Korea
Hyoung-Ryoul Kim, Seoul, Korea

Clinico-pathologic analysis of malignant mesothelioma in Korea
Soon-Hee Jung, Wonju, Korea

Asbestos problems in India: A revisit
V. Subramanian, New Delhi, India

10:30-11:10 The High-Risk Individual III: Poster Discussion

Session Chair: Robert Kratzke (Minneapolis, MN)

DNA methylation profile of 28 candidate marker loci in malignant mesothelioma
Ite Laird-Offringa, Los Angeles, CA

Asbestos exposure and genetic susceptibility to malignant pleural mesothelioma
Stalo Karageorgi, Boston, MA

Effects of long-term supplementation with retinol on plasma, malignant mesothelioma, lung cancer, and potential side effects in the Wittenoom cohort
Helman Alfonso, Crawley, Australia

10:30-10:50 Discussant: Robert Kratzke, Minneapolis, MN

Predictive and/or a diagnostic significance of serum soluble mesothelin related proteins in asbestos-related pleural malignant mesothelioma: Follow-up of a large population of workers previously exposed to asbestos
Luciano Mutti, Vercelli, Italy

Discovery and validation of novel serological biomarkers of mesothelioma
Anil Vachani, Philadelphia, PA

Prediagnostic soluble mesothelin related protein, CA125, CYFRA 21-1 and risk of mesothelioma: A case-control study
Oluf Dimitri Roe, Trondheim, Norway

10:50-11:10 Discussant: Harvey Pass, New York, NY

Posters

Analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma in a general population study

Marta Betti, Novara, Italy

Low-dose computed tomography in workers previously exposed to asbestos: Detection of parenchymal lung disease

Demetris Patsios, Toronto, Canada

Low-dose computed tomography in prior asbestos-exposed workers: Assessment of pleural plaques and screening for lung cancer and malignant mesothelioma

Hamid Bayanati, Toronto, Canada

Soluble mesothelin-related protein is a useful biomarker for malignant mesothelioma developed in Japan

Kazuya Fukuoka, Hyogo, Japan

Combination of cell-surface and soluble mesothelin expressions are required to discern epithelioid mesothelioma cells

Marc Gregoire, Nantes, France

Serum tumor marker of human asbestos-related mesothelioma: Translational research from a hereditary rat cancer model

Okio Hino, Tokyo, Japan

Re-evaluation of plasma osteopontin as a tumor marker for mesothelioma

Kazu Shiomi, Tokyo, Japan

8:00-11:45 Apoptosis Satellite Symposium

Co-Chairs: Courtney Broaddus (San Francisco, CA) and Dean Fennell (Belfast, United Kingdom)

8:00-8:15 An apoptosis primer

Dean Fennell, Belfast, United Kingdom

Session I: Intrinsic pathway and caspases

8:15-8:35 BCL-2 family members in mesothelioma

Michael Lind, Hull, United Kingdom

8:35-8:55 Small molecule inhibition of the BCL-2 family

Saul Rosenberg, Chicago, IL

8:55-9:15 Regulation of cell survival in malignant pleural mesothelioma by Inhibitor of Apoptosis Proteins

Gavin Gordon, Boston, MA

9:15-9:30 DISCUSSION

Session II: The extrinsic pathway and its regulation

9:30-10:00 A novel role of the death receptor CD95 as a tumor promoter

Marcus Peter, Chicago, IL

10:00-10:20 TRAIL and damage pathways converge to induce synergistic apoptosis

Courtney Broaddus, San Francisco, CA

10:20-10:30 DISCUSSION

Session III: Resistance pathways

10:30-10:50 Three-dimensional models of mesothelioma and multi-cellular apoptotic resistance

Dario Barbone, San Francisco, CA

10:50-11:10 Wnt targeted therapies for mesothelioma

David Jablons, San Francisco, CA

11:10-11:30 Receptor tyrosine kinase pathways and cell survival in mesothelioma

Giovanni Gaudino, Novara, Italy

11:30-11:45 DISCUSSION

11:45-1:00 Joint Lunch with the attendees of the Mesothelioma Applied Research Foundation Symposium

1:00-3:10 Surgery and Multi-Modality Therapy for Pleural Mesothelioma: Controversy and Consensus

Session Chairs: Hasan Batirel (Istanbul, Turkey) and Wickii Vigneswaran (Chicago, IL)

1:00-1:15 Pre-operative staging with CT/PET

Mylene Truong, Houston, TX

1:15-1:25 Abstract: Role of preoperative staging procedures using conventional CT-scan, FDG-PET-CT-scan fused imaging, and mediastinoscopy compared to surgical-pathological findings in malignant pleural mesothelioma undergoing extrapleural pneumonectomy

Jens Benn Sorensen, Copenhagen, Denmark

1:25-2:05 DEBATE

There is no role for radical surgery in the management of pleural mesothelioma

Tom Treasure, London, United Kingdom

Surgery for malignant pleural mesothelioma: A guaranteed complete response

Raja Flores, New York, NY

Moderator: Nicholas Vogelzang, Las Vegas, NV

2:05-2:20 Safe implementation of intensity modulated radiation therapy (IMRT) for mesothelioma

Craig Stevens, Tampa, FL

2:20-2:35 Integrating chemotherapy into multi-modality treatment

Rolf Stahel, Zurich, Switzerland

2:35-2:45 Abstract: Multi-center phase II trial of neo-adjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma
Lee Krug, New York, NY

2:45-2:55 Abstract: Induction chemotherapy with cisplatin/gemcitabine compared to cisplatin/pemetrexed followed by extrapleural pneumonectomy for malignant pleural mesothelioma
Walter Weder, Zurich, Switzerland

2:55-3:10 The scientific basis of integrated multimodality regimens
Bruce Robinson, Perth, Australia

Posters

Lung sparing intrapleural and systemic chemotherapy plus intrapleural radiation for pleural mesothelioma: The Columbia protocol
Robert Taub, New York, NY

Sequential amifostine and sodium thiosulfate improve renal protection during intracavitary high-dose cisplatin lavage
William Richards, Boston, MA

Extrapleural pneumonectomy with adjuvant chemo-radiotherapy for treatment of malignant pleural mesothelioma
Rabab Gaafar, Cairo, Egypt

Induction chemotherapy, extrapleural pneumonectomy, and adjuvant hemithoracic radiation in malignant pleural mesothelioma: A single center experience
Federico Rea, Padua, Italy

Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma
Marc de Perrot, Toronto, Canada

The Mesothelioma and Radical Surgery (MARS) trial update
Tom Treasure, London, United Kingdom

Tri-modality treatment of malignant pleural mesothelioma in Turkey
Hasan Batirel, Istanbul, Turkey

Successful multi-modal treatment in primarily chemo-resistant pleural mesothelioma
Helge Bischoff, Heidelberg, Germany

Developing a program for post-operative IMRT in mesothelioma patients following pleurectomy plus phototherapy
Malcolm Feigen, Heidelberg, Australia

Impact of integrated PET-CT on the selection of patients with malignant pleural mesothelioma for radical surgery (extra-pleural pneumonectomy)
Loic Lang-Lazdunski, London, United Kingdom

3:10-3:40 Break/Poster Viewing

3:40-5:55 Chemotherapy: Where Are We and Where Are We Going?

Session Chairs: Jeremy Steele (London, United Kingdom) and Christian Manegold (Mannheim, Germany)

3:40-4:00 New insights into the mechanisms of action of pemetrexed in mesothelioma
I. David Goldman, Bronx, NY

4:00-4:10 Abstract: Pemetrexed but not vinorelbine and cisplatin cytotoxicity is enhanced by COX-2 inhibitors in mesothelioma cell lines
Michael Lind, Hull, United Kingdom

4:10-4:20 Abstract: Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed-induced cell death
Rongbao Zhao, Bronx, NY

4:20-4:40 Combination chemotherapy: Moving beyond pemetrexed
Jan van Meerbeeck, Ghent, Belgium

4:40-4:50 Abstract: Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma
Giovanni Luca Ceresoli, Milan, Italy

4:50-5:00 Abstract: Pemetrexed second-line treatment in malignant pleural mesothelioma following platinum-based first-line treatment
Jens Benn Sorensen, Copenhagen, Denmark

5:00-5:10 Abstract: Vinflunine in first-line treatment of malignant pleural mesothelioma: Final results of a European phase II study
Denis Talbot, Oxford, United Kingdom

The current status of clinical trials in:

5:10-5:25 North America
Lee Krug, New York, NY

5:25-5:40 Europe
Paul Baas, Amsterdam, The Netherlands

5:40-5:55 Australasia
Nick Pavlakis, Sydney, Australia

Posters

Pemetrexed and carboplatin in advanced pleural mesothelioma: Evaluation of the activity and toxicity in a series of 178 chemo-naive patients
Bruno Castagneto, Casale Monferrato, Italy

An epigenetic mechanism for capecitabine resistance in mesothelioma
Kavitha Kosuri, Columbus, OH

Sequential topoisomerase targeting triplet chemotherapy with irinotecan/cisplatin followed by doxorubicin in patients with malignant pleural mesothelioma: A pilot phase II study

Takashi Nakano, Hyogo, Japan

Treatment of malignant pleural mesothelioma with gemcitabine, carboplatin, and liposomized doxorubicin (Caelyx): The CCG study from the Nordic Mesothelioma Groups

Gunnar Hillerdal, Stockholm, Sweden

Treatment with gemcitabine and vinorelbine as second-line chemotherapy in pemetrexed-pretreated patients with malignant pleural mesothelioma

Giovanni Luca Ceresoli, Milan, Italy

Combination chemotherapy with methotrexate, irinotecan, and doxorubicin in malignant pleural mesothelioma

Kozo Kuribayashi, Hyogo, Japan

Pemetrexed in combination with carboplatin for the treatment of patients with malignant mesothelioma

Maximilian Papi, Rimini, Italy

7:00-9:30 Gala Reception at the International Museum of Surgical Science

6:15 Trolleys depart from the Sheraton Chicago Hotel & Towers

7:00-9:30 Reception

9:30 Trolleys return to the Sheraton Chicago Hotel & Towers

Sunday, October 22, 2006

7:00-8:00 Continental Breakfast

8:00-9:45 Novel Targets/Novel Agents I: Agents Currently in Clinical Trials

Session Chairs: Robert Kratzke (Minneapolis, MN) and Luciano Mutti (Vercelli, Italy)

8:00-8:20 Proteasome inhibitors for the treatment of malignant mesothelioma

Luciano Mutti, Vercelli, Italy

8:20-8:35 *Abstract:* Preclinical studies of the proteasome inhibitor bortezomib (Velcade) in malignant pleural mesothelioma

Gavin Gordon, Boston, MA

8:35-8:50 Angiogenesis in mesothelioma

Sarita Dubey, San Francisco, CA

8:50-9:10 Results of phase I clinical trials of adenoviral interferon- gene therapy for malignant mesothelioma and malignant pleural effusions

Daniel Serman, Philadelphia, PA

9:10-9:20 *Abstract:* Calponin-targeting oncolytic Herpes simplex virus (HSV-1) as a novel therapeutic agent for sarcomatous mesothelioma

Katsuhito Takahashi, Osaka, Japan

9:20-9:35 Histone deacetylase inhibitors

Sunil Sharma, Las Vegas, NV

9:35-9:45 *Abstract:* An assessment of Onconase for the treatment of mesothelioma using the CALGB and EORTC paradigms

Joachim von Pawel, Gauting, Germany

Posters

Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma: CALGB 30307

Pasi Janne, Boston, MA

TGF-Beta inhibition augments adenoviral-IFN β (Ad.IFN) gene therapy in a murine mesothelioma model

Samuel Kim, Philadelphia, PA

Asbestos in the past, nanomaterials in the future?

Vanessa Sanchez, Providence, RI

COX-2 specific inhibitors demonstrate a cytotoxic effect independent of COX-2 protein status in vitro

Michael Lind, Hull, United Kingdom

Targeting thioredoxin reductase—a possible new treatment for malignant mesothelioma

Katalin Dobra, Huddinge, Sweden

Preclinical evaluation of histone deacetylase inhibitors in malignant mesothelioma

Sunil Sharma, Las Vegas, NV

9:45-10:05 Break

10:05-11:55 Novel Targets/Novel Agents II: Targets for the Next Generation of Clinical Trials

Session Chairs: Ravi Salgia (Chicago, IL) and Daniel Serman (Philadelphia, PA)

10:05-10:25 IGF pathway activation in mesothelioma

Robert Kratzke, Minneapolis, MN

10:25-10:35 *Abstract:* Effects of insulin-like growth factor binding protein-3 on human malignant pleural mesothelioma cell growth and apoptosis

Cecelia Camacho-Hubner, London, United Kingdom

10:35-10:55 c-met/HGF activation

Ravi Salgia, Chicago, IL

10:55-11:15 A novel small molecule inhibitor of TGF-beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection

Steven Albelda, Philadelphia, PA

11:15-11:25 *Abstract:* A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma

Peter Szlosarek, London, United Kingdom

11:25-11:40 *Abstract:* 17-AAG, an inhibitor of HSP90, suppresses cellular growth of mesothelioma cell lines in vitro

Thomas Gauler, Essen, Germany

11:40-11:55 Nanoporous spheres for drug delivery in mesothelioma

Maria Ramos-Nino, Burlington, VT

Posters

Molecular targeting of malignant pleural mesothelioma by c-met and ROS modulation

Ramasamy Jagadeeswaran, Chicago, IL

Tyrosine kinase inhibitor ZD6474 (Zactima) and its effects on malignant mesothelioma cell lines

Betta Pier-Giacomo, Alessandria, Italy

Activation of 4E-BP1 represses IGF-1 mediated cap dependent translation in malignant pleural mesothelioma

Blake Jacobson, Minneapolis, MN

RNA interference against Hec1 targets malignant mesothelioma

Zeng Zhu, Birmingham, AL

MET in mesothelioma: Mutational screening, phosphorylation status, and sensitivity to the MET inhibitor PHA-665752

Shigeki Shimizu, New York, NY

Biocompatible, hydrophilic, supramolecular carbon nanoparticles for cell delivery

Bonnie Lau, Providence, RI

8:00-12:00 Pathology Workshop

Co-Chairs: Thomas Colby (Rochester, MN), Francoise Galateau-Salle (Caen, France) and Aliya Husain (Chicago, IL)

8:00-10:00 Session I: Current Status of Pathologic Diagnosis of Malignant Mesothelioma

8:00-8:20 Morphologic diagnostic criteria of mesothelioma

Philip Cagle, Houston, TX

8:20-8:40 Atypical mesothelial cell proliferations: Separating mesothelioma from reactive mesothelial hyperplasia

Thomas Colby, Rochester, MN

8:40-9:00 IHC evaluation

Allen Gown, Seattle, WA

9:00-9:20 Molecular studies in diffuse malignant mesothelioma of the pleura

Francoise Galateau-Salle, Caen, France

9:20-9:30 *Abstract:* MUC1 in malignant mesothelioma

Jenette Creaney, Perth, Australia

9:30-9:40 *Abstract:* Diagnostic value of proliferative markers Ki-67 and Repp 86 in distinction between malignant and benign mesothelial proliferations

Zohreh Mohammadtaheri, Teheran, Iran

IMIG Travel Award

9:40-9:50 *Abstract:* Prolonged survival in malignant mesothelioma: A study of 19 cases

Francoise Galateau-Salle, Caen, France

9:50-10:00 *Abstract:* Accuracy of pathological diagnosis of mesothelioma in Japan

Kouki Inai, Hiroshima, Japan

10:00-10:15 BREAK

10:15-12:00 Session II: The Use of Immunohistochemistry Panels in the Diagnosis of Mesothelioma: Guidelines and Recommendations

PANEL DISCUSSION

Posters

Differentiating between malignant mesothelioma and squamous cell carcinoma: An immunohistochemical study

Tiffany Chang, Chicago, IL

Diagnostic utility of GLUT-1 expression in the differential diagnosis between reactive mesothelium and malignant mesothelioma

Yasufumi Kato, Tokyo, Japan

Immunocytochemistry with ten commercially available antibodies in adenocarcinoma cells, malignant or reactive mesothelial cells in serous effusions

Toshiaki Kamei, Hofu, Japan

Prognostic value of fascin immunoreactivity in peritoneal mesothelioma

Alain Borczuk, New York, NY

Utility of CD138, estrogen receptor and progesterone receptor in the differential diagnosis of peritoneal mesothelioma and ovarian adenocarcinoma

Alain Borczuk, New York, NY

A case of malignant mesothelioma with rhabdomyosarcomatous differentiation

Astero Klabatsa, London, United Kingdom

Malignant mesothelioma with signet ring cell formation: A very rare presentation

Sumru Beder, Ankara, Turkey

Malignant tumor with bone formation in a man from Karain village: Mesothelioma or sarcoma?

Gunnar Hillerdal, Stockholm, Sweden

Pathological study of malignant pleural mesothelioma resected with extrapleural pneumonectomy

Kenzo Hiroshima, Chiba, Japan

12:00-12:05 Concluding Remarks

Hedy Lee Kindler and Samuel Armato
IMIG Conference Co-Chairs

12:05 Boxed Lunches

IMIG 2006

Agenda at a Glance

Time	Main Session	Workshop 1	Workshop 2	Workshop 3
Thursday				
8:00	High-Risk Individual I			
10:00	High-Risk Individual II			
11:00	Pathogenesis			
2:30		Chemotherapy Workshop		Animal Models Workshop
Friday				
8:00	Epidemiology I			
10:00	Epidemiology II		Immunology Workshop	
2:00	Genetics			
4:00		Supportive Care Satellite	Tumor Biology: Oral abstracts and poster discussion	Imaging Workshop
Saturday				
8:00	Non-Pleural Mesothelioma		Epidemiology III: Oral abstracts and poster discussion	
10:00	Peritoneal Workshop	Surgical Techniques Workshop	High-Risk Individual: Poster discussion	Apoptosis Satellite
2:00	Surgery and Multimodality Therapy			
4:00	Chemotherapy			
Sunday				
8:00	Novel Agents/ Novel Targets I		Pathology	
10:00	Novel Agents/ Novel Targets II			

CME Information

Statement of Need

This international conference will be a highly interactive, trans-disciplinary meeting, the goals of which are to present scientific information of the highest caliber across disciplines, to foster international collaboration, to inspire new investigators, to generate new ideas, and to establish benchmark standards in this disease. The format will consist of invited lectures, oral abstract presentations, poster presentations, and poster discussion sessions. To foster collaboration and interaction, an important feature of this meeting will be interactive workshops and debates on key issues.

Learning Objectives

After this conference, participants will:

- Understand the best screening methods for mesothelioma—biomarkers, CT scans, thoracoscopy—in patients exposed to asbestos;
- Understand the interaction between genetics and mineral exposure in the development of mesothelioma;
- Understand the mechanisms of the pathogenesis of mesothelioma;
- Describe the epidemiology of asbestos exposure and mesothelioma in countries around the world;
- Understand the genetic alterations caused by asbestos;
- Understand and optimize the clinical management of patients with peritoneal mesothelioma;
- Understand the different multimodality approaches for the management of pleural mesothelioma;
- Understand the activity of various chemotherapeutic agents in patients with mesothelioma;
- Understand the optimal therapeutic targets for the next generation of clinical trials for mesothelioma;
- Understand the clinical relevance of mouse models for mesothelioma;
- Understand key questions that need to be answered in order to develop the next generation of chemotherapy clinical trials for mesothelioma;
- Understand the immunology of mesothelioma and immunotherapeutic approaches for treatment;
- Understand the current controversies involved in imaging mesothelioma;
- Understand the key issues in supportive care for mesothelioma patients;
- Understand apoptosis in mesothelioma;
- Understand the optimal treatment, staging, and clinical trial design for peritoneal mesothelioma;
- Learn technical skills about the surgical management of mesothelioma;
- Understand the current status of the pathologic diagnosis of mesothelioma and make recommendations on the use of immunohistochemistry panels.

Target Audience

Medical oncologists, surgeons, radiation oncologists, pulmonologists, epidemiologists, radiologists and basic scientists who research mesothelioma or treat patients with this disease.

Accreditation

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

Credit Designation

The University of Chicago Pritzker School of Medicine designates this educational activity for a maximum of 24.50 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Additional Information

The University of Chicago
The Center for Continuing Medical Education
950 E. 61st Street, Room 101
Chicago, IL 60637
Phone: 773-702-1056
Fax: 773-702-1736
cme@bsd.uchicago.edu
<http://cme.uchicago.edu>

Acknowledgements

Notes

The conference organizers wish to extend our sincerest thanks to the following for financial support received for the IMIG meeting:

Cooney & Conway

Richardson, Patrick, Westbrook & Brickman, LLC

Kazan, McClain, Abrams, Fernandez, Lyons,
Farrise & Greenwood

Law Office of Nicholas J. Vogelzang

Merck

Simmons Cooper, LLC

Terrence M. Johnson, Esq.

Eli Lilly and Company

AstraZeneca

Roger Worthington, PC

Cambridge Antibody Technologies

Bristol-Myers Squibb Oncology



iMig
International Mesothelioma Interest Group

Devoted to the biology & pathology of mesothelial cells.